๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Her 2 Positive Breast Cancer

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cediranib, Ceralasertib, Olaparib Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks NCT05212454Phase 31 site๐Ÿ“ Hanzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Capecitabine A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine HER2+ CNS Surveillance NCT07748598NA1 site๐Ÿ“ Liverpool The Clatterbridge Cancer Centre NHS Foundation Trust ยท Tests: Intervention for Arm 2: Brain MRI Surveillance RADIANT: Pre-op Radiation With Abemaciclib and Letrozole NCT06139107Phase 14 sites๐Ÿ“ Belleville๐Ÿ“ Livingston๐Ÿ“ New Brunswick Mridula George, MD ยท Tests: Abemaciclib, Letrozole PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan NCT05573893n/a109 sites๐Ÿ“ Amberg๐Ÿ“ Ansbach๐Ÿ“ Apolda AstraZeneca Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab NCT05760612Phase 31 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Trastuzumab and neratinib, Trastuzumab and Pertuzumab A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer NCT07658183Phase 21 site๐Ÿ“ Shanghai Shanghai Best-Link Bioscience, LLC ยท Tests: BL0175 Injection, BL0175 Injection Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. NCT07227233Phase 21 site๐Ÿ“ La Jolla University of California, San Diego ยท Tests: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physiciaโ€ฆ Gene Therapy for HER-Positive Cancer (SENTRY-HER2) NCT07192432Phase 1, Phase 211 sites๐Ÿ“ Los Angeles๐Ÿ“ Denver๐Ÿ“ Jacksonville Vironexis Biotherapeutics Inc. ยท Tests: Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202, Dose Level 4, VNX-202 Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer NCT06062498Phase 23 sites๐Ÿ“ Chicago๐Ÿ“ Chicago๐Ÿ“ Chicago Northwestern University ยท Tests: elacestrant, palbociclib, abemaciclib, ribociclib Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion โ€ฆ ยท Tests: GTAEXS617, SoC A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer NCT06369285Phase 253 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Beverly Hills Puma Biotechnology, Inc. ยท Tests: Alisertib, Endocrine therapy Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC NCT07671092EARLY Phase 16 sites๐Ÿ“ St Leonards๐Ÿ“ Nedlands๐Ÿ“ Perth RayzeBio, Inc. ยท Tests: RYZ211/212 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites๐Ÿ“ Gilbert๐Ÿ“ Beverly Hills๐Ÿ“ Duarte Relay Therapeutics, Inc. ยท Tests: Zovegalisib, Capivasertib, Fulvestrant A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer NCT04872166Phase 16 sites๐Ÿ“ Lake Mary๐Ÿ“ Sarasota๐Ÿ“ Cincinnati Edgewood Oncology Inc. ยท Tests: BTX-A51 Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites๐Ÿ“ Phoenix๐Ÿ“ Irvine๐Ÿ“ San Diego RayzeBio, Inc. ยท Tests: RYZ101, Standard of Care Endocrine Therapy NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline NCT06452394Phase 28 sites๐Ÿ“ Sankt Gallen๐Ÿ“ Genolier๐Ÿ“ Winterthur Swiss Cancer Institute ยท Tests: Doxycyclin A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer NCT06202261Phase 1, Phase 22 sites๐Ÿ“ Chongqing๐Ÿ“ Harbin Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ยท Tests: TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule, Fulvestrant injection, Capecitabine tโ€ฆ FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Port Saint Lucie Regor Pharmaceuticals Inc. ยท Tests: RGT-419B, RGT-419B in combination with hormonal therapy A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor NCT07612891Phase 1, Phase 21 site๐Ÿ“ Shanghai Shenzhen Ionova Life Sciences Co., Ltd. ยท Tests: INV-6452 A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer NCT07757230Phase 21 site๐Ÿ“ Guangzhou Shenyang Sunshine Pharmaceutical Co., LTD. ยท Tests: SSGJ-612 (HER2-targeted antibody), HER2-targeted ADC A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) NCT07541079Phase 38 sites๐Ÿ“ Fountain Valley๐Ÿ“ Stockton๐Ÿ“ Washington D.C. Genentech, Inc. ยท Tests: Giredestrant Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer NCT05910398Phase 31 site๐Ÿ“ Shanghai RenJi Hospital ยท Tests: pyrotinib BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer NCT06756932Phase 114 sites๐Ÿ“ Iowa City๐Ÿ“ Houston๐Ÿ“ Seattle BeOne Medicines ยท Tests: BGB-21447, Fulvestrant, BGB-43395 Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab NCT05325632Phase 21 site๐Ÿ“ Tampa H. Lee Moffitt Cancer Center and Research Institute ยท Tests: HER-2 pulsed DC1, Trastuzumab, Pertuzumab, Paclitaxel, Resection surgery S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer NCT03723928NA723 sites๐Ÿ“ Anchorage๐Ÿ“ Anchorage๐Ÿ“ Anchorage SWOG Cancer Research Network ยท Tests: Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Quesโ€ฆ Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy NCT02945579NA8 sites๐Ÿ“ Gilbert๐Ÿ“ Jacksonville๐Ÿ“ Honolulu M.D. Anderson Cancer Center ยท Tests: Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast Iโ€ฆ Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive๏ผŒ Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer NCT07796880Phase 21 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Culmerciclib, Aromatase Inhibitor (AI)
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy